Cytokinetics, Incorporated
Cytokinetics, Incorporated (CYTK) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cytk · stock forecast · 35 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 35 Wall Street analysts in the past 3 months
Buy
35 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$140
Consensus
$99.92
+44.0% upside
Low
$83.00
Median: $99 · Last Close: $69.41
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$99.92
44.0% upside
High Target
$140
101.7%
Low Target
$83
19.6%
Current Price
$69.41
as of today
Based on analyst price targets, the CYTK stock price prediction for the next 12 months ranges from $83 to $140. The consensus CYTK price forecast of $99.92 implies 44.0% upside from the current price of $69.41.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $66.87 | ↓ 3.66% |
1-day model range: $66.37–$67.36. Peak: $67.36 (-3.66%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CYTK · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-12 | JP Morgan | Maintains | Overweight→Overweight |
| 2026-05-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-05-07 | Wells Fargo | Maintains | Overweight→Overweight |
| 2026-05-06 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2026-05-06 | Stifel | Maintains | Buy→Buy |
| 2026-05-06 | RBC Capital | Maintains | Outperform→Outperform |
| 2026-05-05 | Needham | Maintains | Buy→Buy |
| 2026-04-06 | Barclays | Maintains | Overweight→Overweight |
| 2026-03-18 | Mizuho | Maintains | Outperform→Outperform |
| 2026-03-17 | JP Morgan | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Cytokinetics, Incorporated (CYTK) stock. Of the recent 217 rating actions, 5 were upgrades and 9 were downgrades. 35 analysts currently cover CYTK.
Analyst Recommendation Trends
CYTK analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 8 to 7 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$105M
↓ 88.0% YoY
Revenue Next Year
$388M
↑ 268.0% YoY
EPS This Year
$-6.38
EPS Next Year
$-4.59
↓ 28.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast CYTK EPS of $-6.38 for the current fiscal year, based on estimates from 15 analysts. The CYTK revenue forecast is $105M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CYTK stock forecast is supported by two independent data sources: analyst consensus ratings from 35 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CYTK price target is $99.92 (+44.0% upside), with an analyst consensus of Buy.
The CYTK short-term stock prediction for tomorrow is $66.87 (-3.66%).
Cytokinetics, Incorporated trades on NASDAQ under the ticker CYTK. The CYTK stock outlook for 2027 is broadly positive, supported by a Buy consensus among 94% of covering analysts.
Frequently asked questions
CYTK forecast · 8 questionsAccording to 35 Wall Street analysts, the average 12-month CYTK price target is $99.92, with a high forecast of $140.00 and a low of $83.00. The median price target is shown in the chart above when available. This implies +44.0% potential upside from the current price of $69.41.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.